Related Experiment Video

Updated: Aug 6, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Beyond Weight Loss: Early Real-World Evidence of Semaglutide in Obesity

Steluța Constanța Boroghină1,2,3, Amalia-Ioana Arhire1, Teodora Papuc1,4

  • 1Kilostop Junior Nutrition Clinic, 010073 Bucharest, Romania.

Medicines (Basel, Switzerland)
|July 24, 2026
PubMed

Insights

Semaglutide, a glucagon-like peptide-1 receptor agonist, significantly reduced weight and improved insulin resistance in a real-world obesity cohort within three months. This study highlights Semaglutide

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Obesity is a complex, chronic disease often resistant to lifestyle interventions alone.
  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are emerging as effective treatments for obesity.
  • Limited prospective real-world data exist on the efficacy of GLP-1 RAs like Semaglutide.

Purpose of the Study:

  • To prospectively evaluate the effects of once-weekly Semaglutide on weight, body composition, and metabolic health in patients with obesity.
  • To assess the real-world effectiveness of Semaglutide in a diverse patient population, including children and adolescents.

Main Methods:

  • An exploratory observational study involving 37 patients initiating Semaglutide treatment for obesity.
  • Measurements included anthropometry, bioimpedance body composition, and fasting biochemistry at baseline and 3 months.
  • Statistical analyses used parametric or non-parametric paired tests, with a significance level of α = 0.05.

Main Results:

  • A median weight reduction of 8.0 kg and BMI decrease of 1.6 kg/m² was observed after 3 months (p < 0.001).
  • Body fat percentage decreased (p = 0.009), with a minor reduction in skeletal muscle mass (p = 0.035).
  • Significant improvements in fasting glucose (p = 0.030) and insulin resistance (HOMA-IR) were noted, alongside a decrease in triglycerides.

Conclusions:

  • Once-weekly Semaglutide demonstrated rapid and clinically meaningful improvements in weight, adiposity, and insulin resistance within 3 months in a real-world setting.
  • Semaglutide shows promise as an effective adjunct to lifestyle therapy for obesity management.
  • Further research is warranted to explore the long-term effects and broader applications of Semaglutide in obesity treatment.
Keywords:
GLP-1 RAsmetabolic syndromeobesity treatmentpediatric obesityreal-world evidence

More Related Videos

Sleeve Gastrectomy in Mice using Surgical Clips05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...